REG - IXICO plc - Contract worth circa £800k

IXICOAnnouncement

08/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220308:nRSH9110Da&default-theme=true

RNS Number : 9110D  IXICO plc  08 March 2022

IXICO plc

("IXICO" or the "Company")

 

Contract awarded for Phase 1b/2 Huntington's disease trial worth circa £800k

 

Reflection on IXICO's ability and expertise within the Huntington's disease
trials space

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience announces that it has been
selected by an existing US biotech client to provide PET and MRI neuroimaging
services for an open-label Phase I/II dose finding study. The study will
evaluate the safety, tolerability, and preliminary efficacy of the client's
gene-therapy drug candidate in adult subjects with early manifest Huntington's
disease (HD).  The trial is due to run for just over five years and is worth
circa £800k.

 

This is IXICO's second study for this client, having previously won a contract
in 2021 to support a Multiple System Atrophy study.

 

Having provided centralised neuroimaging CRO services, including advanced
imaging biomarker analysis, across many Huntington's disease trials, IXICO has
developed and validated disease-optimised advanced analytics technology for
this indication. This, together with the ability to deliver these services
through the Company's proprietary TrialTracker data management platform,
combined with the Company's extensive experience in supporting Huntington's
disease trials, make IXICO the leading choice as the partner for this study.

 

Chris Hamilton, SVP Commercial at IXICO, commented: "We are delighted to play
an important role in the development of this exciting gene therapy in a
disease area we know extremely well and where we will deploy both our MRI and
PET expertise. This new contract with an existing client reflects the
confidence of our clients in the use of our services across different CNS
development programmes within their portfolio. Our purpose is to support our
clients in their tireless efforts to bring potential treatments to patients
suffering from neurological disorders."

 

For further information please contact:

 

 IXICO plc                                                  +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                   +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

 Walbrook PR Ltd     +44 (0)20 7933 8780

 Paul McManus / Lianne Applegarth /      IXICO@walbrookpr.com
 Alice Woodings

 

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com (http://www.IXICO.com)  and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEDLFBLXLZBBQ